Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Michael Schlag
Observed names:
M G Schlag,
M Schlag,
M. G. Schlag,
M. Schlag,
MG Schlag,
MICHAEL G. SCHLAG,
Michael G. Schlag,
Michael George Schlag
show all 8
Observed institutions:
Western University,
University of Vienna,
London Health Sciences Centre,
Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA,
Baxter (Austria),
Victoria Hospital,
Gilead Sciences (United States),
Gilead Sciences (Germany)
show all 8
OpenAlex ID:
A5111692586
Tranexamic Acid, a Widely Used Antifibrinolytic Agent, Causes Convulsions by a γ-Aminobutyric AcidA Receptor Antagonistic Effect
2002
·
Roman Furtmüller
, Michael G. Schlag
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
211
Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
2015
·
Christoph Sarrazin
, Erkki Lathouwers
, et al.
·
Antiviral Research
·
108
PDF
Convulsive Seizures Following Subdural Application of Fibrin Sealant Containing Tranexamic Acid in a Rat Model
2000
·
Michael G. Schlag
, Rudolf Hopf
, et al.
·
Neurosurgery
·
75
The effect of ketamine/xylazine anesthesia on sensory and motor evoked potentials in the rat
2002
·
S Zandieh
, R Hopf
, et al.
·
Spinal Cord
·
67
Epileptic Seizures Following Cortical Application of Fibrin Sealants Containing Tranexamic Acid in Rats
2002
·
M. G. Schlag
, R. Hopf
, et al.
·
Acta Neurochirurgica
·
62
Ischemic tolerance in skeletal muscle: role of nitric oxide
1998
·
S. Pudupakkam
, K. A. Harris
, et al.
·
American Journal of Physiology-Heart and Circulatory Physiology
·
37
Role of leukocyte accumulation and oxygen radicals in ischemia-reperfusion-induced injury in skeletal muscle
2001
·
M. G. Schlag
, K. A. Harris
, et al.
·
American Journal of Physiology-Heart and Circulatory Physiology
·
29
Economic burden of late presentation in HIV disease in Austria: a comparison of the initial costs imposed by advanced HIV disease vs. non-late presentation
2013
·
Katharina Grabmeier-Pfistershammer
, Armin Rieger
, et al.
·
Wiener klinische Wochenschrift
·
15
The long-term effects of pre-treatment with activated protein C in a rat model of compression-induced spinal cord injury
2000
·
Y Taoka
, MG Schlag
, et al.
·
Spinal Cord
·
14
The effect of mannitol versus dimethyl thiourea at attenuating ischemia/reperfusion-induced injury to skeletal muscle
1999
·
Michael George Schlag
, Sharon Clarke
, et al.
·
Journal of Vascular Surgery
·
13
PDF
Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response
2017
·
Tarik Asselah
, Christophe Moreno
, et al.
·
PLoS ONE
·
9
PDF
Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape
2016
·
Jan Fehr
, Dunja Nicca
, et al.
·
Infection
·
8
Efficacy and safety of Simeprevir-containing hepatitis C therapy in patients on opiate substitution therapy
2017
·
J. Dillon
, S. Mauss
, et al.
·
Journal of Hepatology
·
7
Efficient Carboplatin Single Therapy in a Mouse Model of Human Testicular Nonseminomatous Germ Cell Tumor
2002
·
SEYEDHOSSEIN AHARINEJAD
, MELANIE FINK
, et al.
·
The Journal of Urology
·
7
Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease
2017
·
Christophe Hézode
, Piero L. Almasio
, et al.
·
Liver International
·
5
Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection.
2017
·
Gianpiero D'Offizi
, Calogero Cammà
, et al.
·
PubMed
·
5
Convulsive Seizures Following Subdural Application of Fibrin Sealant Containing Tranexamic Acid in a Rat Model
2001
·
Michael Schlag
·
Neurosurgery
·
5
An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1)
2016
·
Tarik Asselah
, Christophe Moreno
, et al.
·
PLoS ONE
·
4
PDF
Evolution of HCV patient characteristics and DAA regimens in the German Hepatitis C Registry (DHC-R) in 2014 and 2015
2019
·
Christoph Sarrazin
, Peter Buggisch
, et al.
·
Zeitschrift für Gastroenterologie
·
3
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications
2018
·
Fiona Marra
, Christoph Höner zu Siederdissen
, et al.
·
British Journal of Clinical Pharmacology
·
3
PDF
Consistent Simeprevir Resistance Profile in Hepatitis C Virus Genotype 1-Infected Patients Failing Simeprevir Interferon-Free Compared with Interferon-Containing Regimens
2016
·
B. Fevery
, L. Vijgen
, et al.
·
Journal of Hepatology
·
2
Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis
2016
·
C. Hezode
, P. Almasio
, et al.
·
Journal of Hepatology
·
2
Late versus non‐late presentation of HIV/AIDS: an economic impact analysis
2010
·
K Grabmeier‐Pfistershammer
, A Rieger
, et al.
·
Journal of the International AIDS Society
·
2
PDF
Hind Limb Hyperexcitability Following the Application of Fibrin Sealants Containing Tranexamic Acid to the Lumbar Spinal Cord in Rats
2002
·
Michael G. Schlag
, Rudolf Hopf
, et al.
·
European Journal of Trauma
·
2
P0792 : Baseline factors associated with increased SVR rates in 123 treatment-naïve chronic HCV genotype 1 patients treated with a shortened 12-week simeprevir plus pegylated interferon and ribavirin regimen: a multivariate analysis
2015
·
T. Asselah
, C. Moreno
, et al.
·
Journal of Hepatology
·
1
Show more works
View as search
Works count:
36
Citation count:
697
H-index:
10
I10-index:
10
Year
Topic
Type
